Andrea Tan
Stock Analyst at Goldman Sachs
(2.76)
# 2,820
Out of 5,162 analysts
53
Total ratings
39.02%
Success rate
0.34%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Andrea Tan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KRYS Krystal Biotech | Maintains: Buy | $206 → $327 | $247.26 | +32.25% | 2 | Feb 2, 2026 | |
| ARWR Arrowhead Pharmaceuticals | Maintains: Neutral | $50 → $85 | $55.05 | +54.41% | 3 | Jan 7, 2026 | |
| INSM Insmed | Maintains: Buy | $258 → $225 | $139.50 | +61.29% | 15 | Dec 18, 2025 | |
| IOVA Iovance Biotherapeutics | Maintains: Buy | $16 → $8 | $3.96 | +102.02% | 7 | May 12, 2025 | |
| TARS Tarsus Pharmaceuticals | Maintains: Neutral | $46 → $51 | $67.96 | -24.96% | 4 | May 5, 2025 | |
| DAWN Day One Biopharmaceuticals | Maintains: Buy | $39 → $27 | $21.31 | +26.70% | 6 | Mar 25, 2025 | |
| SGMT Sagimet Biosciences | Maintains: Neutral | $23 → $6 | $5.21 | +15.16% | 5 | Jul 1, 2024 | |
| RLMD Relmada Therapeutics | Downgrades: Sell | $3 → $2 | $5.91 | -66.16% | 3 | Jun 5, 2024 | |
| KOD Kodiak Sciences | Reinstates: Sell | $2 | $23.19 | -91.38% | 1 | Dec 11, 2023 | |
| ABCL AbCellera Biologics | Maintains: Buy | $27 → $24 | $3.49 | +587.68% | 2 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $10 → $4 | $1.17 | +241.88% | 2 | Jan 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $178 → $375 | $444.83 | -15.70% | 1 | Dec 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $120 → $80 | $13.48 | +493.47% | 2 | May 24, 2022 |
Krystal Biotech
Feb 2, 2026
Maintains: Buy
Price Target: $206 → $327
Current: $247.26
Upside: +32.25%
Arrowhead Pharmaceuticals
Jan 7, 2026
Maintains: Neutral
Price Target: $50 → $85
Current: $55.05
Upside: +54.41%
Insmed
Dec 18, 2025
Maintains: Buy
Price Target: $258 → $225
Current: $139.50
Upside: +61.29%
Iovance Biotherapeutics
May 12, 2025
Maintains: Buy
Price Target: $16 → $8
Current: $3.96
Upside: +102.02%
Tarsus Pharmaceuticals
May 5, 2025
Maintains: Neutral
Price Target: $46 → $51
Current: $67.96
Upside: -24.96%
Day One Biopharmaceuticals
Mar 25, 2025
Maintains: Buy
Price Target: $39 → $27
Current: $21.31
Upside: +26.70%
Sagimet Biosciences
Jul 1, 2024
Maintains: Neutral
Price Target: $23 → $6
Current: $5.21
Upside: +15.16%
Relmada Therapeutics
Jun 5, 2024
Downgrades: Sell
Price Target: $3 → $2
Current: $5.91
Upside: -66.16%
Kodiak Sciences
Dec 11, 2023
Reinstates: Sell
Price Target: $2
Current: $23.19
Upside: -91.38%
AbCellera Biologics
Aug 4, 2023
Maintains: Buy
Price Target: $27 → $24
Current: $3.49
Upside: +587.68%
Jan 9, 2023
Maintains: Sell
Price Target: $10 → $4
Current: $1.17
Upside: +241.88%
Dec 20, 2022
Maintains: Buy
Price Target: $178 → $375
Current: $444.83
Upside: -15.70%
May 24, 2022
Maintains: Neutral
Price Target: $120 → $80
Current: $13.48
Upside: +493.47%